GGrantIndex
Sort

21,453 grants matching tuberculosis

Chemical probes of vulnerable pathways in antibiotic-resistant pathogens

$747,835
Tanya Parish · Access To Advanced Health Institute · R01 · FY2012 · AI

Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria

$747,825
Robert B Abramovitch · Michigan State University · R01 · FY2024 · AI

Treating Sleep Apnea in Type 2 Diabetes Mellitus: A Randomized Clinical Trial

$747,774
Naresh Punjabi · Johns Hopkins University · R01 · FY2014 · HL

Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen

$747,759
Abraham Pinter · Rbhs-New Jersey Medical School · R01 · FY2021 · AI

Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis

$747,745
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2022 · AI

Immune correlates of tuberculosis and non-tuberculosis infectious morbidity in Southern African HIV-exposed, uninfected infants.

$747,678
Kathleen Powis · Massachusetts General Hospital · R01 · FY2021 · AI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation

$747,665
Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · AI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation

$747,665
Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · AI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation

$747,665
Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · AI

Aerobiology, immunology, and Mycobacterium tuberculosis transmission

$747,406
David J. Horne · University Of Washington · R01 · FY2023 · AI

IgM in the regulation of TB immunity

$747,370
John R. Chan · Rbhs-New Jersey Medical School · R01 · FY2022 · AI

Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen

$747,342
Abraham Pinter · Rutgers Biomedical And Health Sciences · R01 · FY2023 · AI

Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen

$747,342
Abraham Pinter · Rbhs-New Jersey Medical School · R01 · FY2022 · AI

Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr

$747,226
Kirill Ostanin · Navigen, Inc. · R44 · FY2014 · AR

East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium

$747,173
Kara Kay Wools-Kaloustian · Indiana University Indianapolis · U01 · FY2025 · AI

Translational approaches to improve understanding and outcome in Tuberculous meningitis

$747,157
Martin Alfons Gengenbacher · Hackensack University Medical Center · R01 · FY2024 · AI

Macaque Models of AIDS-Related Tuberculosis and T Cell

$746,953
University Of Illinois At Chicago · R01 · FY2005 · HL

Task A19: In Vitro Assessment of Anti-Microbial Activity

$746,950
Tanya Parish · Access To Advanced Health Institute · N01 · FY2015 · AI

COMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANS

$746,671
Shabaana A. Khader · Washington University · R01 · FY2016 · AI

Novel therapeutics to treat TB by stimulating bacterial cAMP production

$746,602
Brian C Vanderven · Cornell University · R01 · FY2025 · AI

Precision immunoprofiling to reveal diagnostic biomarkers of latent TB infection

$746,475
Ryan C Bailey · University Of Michigan At Ann Arbor · R01 · FY2021 · AI

Developmental Core (Core B)

$746,336
John Koethe · Vanderbilt University Medical Center · P30 · FY2022 · AI

Center for Humanized Mice

$746,325
Larisa Y Poluektova · University Of Nebraska Medical Center · R24 · FY2016 · OD

Exploratory Chemistry on a new antibiotic

$746,210
Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2016 · AI

Project 2: Response to Treatment

$746,072
David R Sherman · Seattle Children'S Hospital · U19 · FY2022 · AI